ALPL Genotype

You break a bone from something that should not have broken it. You lose adult teeth without an obvious reason. Your bone density looks low and your doctor reaches for a standard osteoporosis drug. Before any of that, it can help to know whether you carry a variant in your ALPL gene, the genetic blueprint for an enzyme that lets bone and tooth tissue harden properly.

ALPL (alkaline phosphatase, liver/bone/kidney) genetic testing identifies inherited changes that cause hypophosphatasia, a condition where bones and teeth do not mineralize the way they should. The result is permanent, the answer is one-time, and the implications shape decisions for the rest of your life, including which osteoporosis treatments are safe for you.

What the ALPL Gene Does

The ALPL gene contains the instructions for making an enzyme called tissue-nonspecific alkaline phosphatase, or TNSALP. This enzyme sits on the outer surface of cells in bone, liver, kidney, developing teeth, and the capillaries of the blood-brain barrier. Its main job is to clear away molecules that would otherwise block the formation of hydroxyapatite, the mineral crystal that gives bones and teeth their hardness.

When ALPL carries a loss-of-function variant, the enzyme it produces is partly or entirely broken. A natural inhibitor of bone hardening called inorganic pyrophosphate then builds up, and minerals struggle to lock into the bone framework. The active (phosphorylated) form of vitamin B6 also accumulates outside cells because TNSALP normally removes its phosphate group so B6 can cross into cells. In severe cases, this can trigger seizures in infants. This entire condition is called hypophosphatasia, often shortened to HPP.

Hypophosphatasia: The Disease This Test Detects

Hypophosphatasia is unusual among inherited bone diseases because the severity varies enormously, from a lethal form in newborns to adults who go decades without realizing they have it. The pattern of inheritance matters. People who inherit two severe variants (one from each parent) tend to have the most dangerous infantile forms, with profound bone disease and sometimes brain involvement. People who inherit a single variant or two milder variants often present in adulthood with broken teeth, stress fractures in the feet, or unexplained musculoskeletal pain.

Adult HPP is frequently missed. In one large laboratory survey of more than 6.9 million alkaline phosphatase measurements, about 0.52% showed the biochemical signature of HPP (persistently low alkaline phosphatase plus elevated vitamin B6 substrate). Among adults referred specifically because their alkaline phosphatase was persistently low, roughly half carried an ALPL variant. People with this condition often spend years being treated for the wrong diagnosis, including fibromyalgia or standard osteoporosis.

Bones and Fractures

Skeletal symptoms are the most consistent thread across HPP severity. Children may show rickets-like deformities and short stature; adults may have recurrent metatarsal fractures, femoral shaft fractures, or stress fractures that heal slowly. In a study of 56 adults with low TNSALP activity, those carrying common ALPL variants had a higher rate of metatarsal fractures than non-carriers.

There is an important implication for anyone diagnosed with low bone density. Osteoporosis clinics that screened 1,839 patients found that a low alkaline phosphatase level should prompt consideration of HPP before treatment begins. Bisphosphonates and similar antiresorptive drugs (the standard osteoporosis class) have been linked in case reports and case series to atypical femoral fractures in people with HPP, and current expert guidance recommends avoiding them in this group. Knowing your ALPL status before starting these drugs is not a curiosity. It changes which treatments are safe.

Teeth and Dental Loss

Premature loss of baby teeth with their roots still attached is one of the most specific early signs of HPP and is included in international diagnostic criteria. In adults, the dental signature is short-rooted permanent teeth, cementum defects, and tooth loss without obvious gum disease. A dentist is often the first clinician to suspect HPP, sometimes years before the bone symptoms are addressed.

Neurologic and Vitamin B6 Effects

TNSALP removes the phosphate group from the active form of vitamin B6 (pyridoxal-5'-phosphate, or PLP) so it can cross cell membranes and reach the brain and other tissues. When the enzyme is missing or weakened, PLP accumulates in the blood but cannot get into cells. In severe infantile HPP, this can cause seizures that respond to B6. A case report of an infant with two severe ALPL variants described progressive brain injury, suggesting the enzyme plays a role in brain development. In milder adult forms, neurologic involvement is uncommon, but the same vitamin B6 handling defect can be measured biochemically and used to support diagnosis.

Why a Single Reading Is Enough

Your ALPL genotype is fixed at conception and does not change. There is no need to retest the gene itself, no useful trend to track, and no biological variability to average out. What does change over time is the consequence of the variant, including bone density, fracture risk, and dental health. Once you have the genotype, the value comes from acting on it for decades, not from repeating the test.

If you carry a variant, the practical follow-through is to measure your serum alkaline phosphatase periodically, track vitamin B6 (PLP) levels if relevant, monitor bone density with DEXA, and stay alert for fractures or dental changes. These companion tests are what get retested over time, not the gene itself.

What an Out-of-Pattern Result Should Prompt

If your ALPL test identifies a pathogenic or likely pathogenic variant, the next steps are practical. Order a serum alkaline phosphatase, with attention to age and sex adjustment, because low values support the diagnosis. Add a vitamin B6 (pyridoxal-5'-phosphate) level, since elevations strengthen the biochemical case. Get a DEXA scan to baseline your bone density. If you have unexplained fractures, talk to a metabolic bone specialist or endocrinologist familiar with HPP rather than starting a standard osteoporosis drug. Enzyme replacement therapy with asfotase alfa is FDA-approved for perinatal, infantile, and juvenile-onset HPP, and registry data have also shown sustained improvements in mobility and quality of life in adults treated off-label.

If your result is a variant of uncertain significance, the answer is not yet final. Variant databases are actively being updated, and a recent reclassification project moved 100 ALPL variants into clearer categories by combining laboratory tests of how much enzyme activity each variant retains with standard genetic interpretation rules. Pair the genetic result with biochemistry and a clinical exam rather than relying on the genotype call alone.

Family Implications

ALPL variants are inherited, which means your siblings, children, and biological parents may carry the same variant. In one study of 114 family members of people with known ALPL variants, biochemical abnormalities were common in carriers even when full clinical symptoms were not. Carrying a variant does not guarantee disease. A study of 37,147 people in an unselected biorepository found that adults carrying pathogenic or likely pathogenic ALPL variants had low rates of classic symptoms; only about 13% met full diagnostic criteria for HPP. The variant raises risk, but does not seal fate.

When Results Can Be Misleading

Genetic tests are highly reliable for the specific variants they look for, but a few caveats matter:

• Panel coverage: the assay only detects variants it is designed to detect. A negative result does not rule out every rare or novel variant in ALPL, and direct-to-consumer reports (like 23andMe) cover fewer variants than clinical-grade sequencing.
• Variant of uncertain significance (VUS): sometimes a variant is found but its clinical meaning is not yet clear. Interpretation may change as more data accumulate.
• Ancestry effects: some ALPL variants are common in one population and rare in another, so the clinical weight of a result depends on your background.
• Genetics alone does not equal disease: carriers can be biochemically abnormal but symptom-free for life. The diagnosis of hypophosphatasia requires combining the variant with low alkaline phosphatase, elevated substrates, and clinical signs.